Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Conditions:   Advanced Solid Tumors;   NSCLC;   Bladder Cancer;   HNSCC;   Renal Cancer;   Melanoma;   Anal Cancer;   Colorectal Cancer;   Cholangiocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma Interventions:   Drug: Continue PD-1/PD-L1 Inhibitors treatment;   Other: Discontinue PD-1/PD-L1-1 inhibitor Sponsor:   Antoinette J Wozniak Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Gastroenterology | HNSCC | Melanoma | Non-Small Cell Lung Cancer | Research | Skin Cancer